Myeloma patients over age 70 can benefit from auto-HC transplantDecember 7, 2019Multiple MyelomaTransplant
Bispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Multiple MyelomaCellular Therapy
High complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Multiple MyelomaCellular Therapy
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTENovember 26, 2019Cellular TherapyALLMultiple Myeloma
Foundation launches direct-to-patient registry in multiple myelomaNovember 13, 2019Multiple MyelomaPatient & Survivor Care
Levofloxacin prophylaxis improves survival in newly diagnosed myelomaNovember 1, 2019Multiple Myeloma
SEER analysis reveals medication adherence factors in newly diagnosed myelomaOctober 24, 2019Multiple Myeloma
Second-generation anti-BCMA CAR T-cell therapy shows promise in myeloma trialSeptember 27, 2019Multiple Myeloma
Daratumumab approved in combo with VTd for transplant-eligible multiple myelomaSeptember 26, 2019Multiple MyelomaTransplant
Subcutaneous and IV daratumumab combos appear comparable in myelomaSeptember 26, 2019Multiple Myeloma
Quadruplet prolongs progression-free survival in newly diagnosed myelomaSeptember 26, 2019Multiple Myeloma
